Clinical Trial Update: Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the pharmacokinetics, safety and efficacy of nemolizumab in adults with moderate-to-severe atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Nemolizumab (nemolizumab)

Snippet

Sponsor: Galderma R&D | Conditions: Moderate-to-Severe Atopic Dermatitis | Phase 2 | Status: COMPLETED